Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative

LG. Rider, R. Aggarwal, A. Pistorio, N. Bayat, B. Erman, BM. Feldman, AM. Huber, R. Cimaz, RJ. Cuttica, SK. de Oliveira, CB. Lindsley, CA. Pilkington, M. Punaro, A. Ravelli, AM. Reed, K. Rouster-Stevens, A. van Royen-Kerkhof, F. Dressler, C. Saad...

. 2017 ; 76 (5) : 782-791.

Language English Country England, Great Britain

Document type Consensus Development Conference, Journal Article, Practice Guideline, Validation Study

Persistent link   https://www.medvik.cz/link/bmc17023152

To develop response criteria for juvenile dermatomyositis (DM). We analysed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute per cent change in core set measures of minimal (≥30), moderate (≥45), and major (≥70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (p=0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (p<0.006). The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute per cent change in core set measures, with thresholds for minimal, moderate, and major improvement.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023152
003      
CZ-PrNML
005      
20170720123508.0
007      
ta
008      
170720s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/annrheumdis-2017-211401 $2 doi
035    __
$a (PubMed)28385804
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rider, Lisa G $u NIEHS, NIH, Bethesda, Maryland, USA.
245    10
$a 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative / $c LG. Rider, R. Aggarwal, A. Pistorio, N. Bayat, B. Erman, BM. Feldman, AM. Huber, R. Cimaz, RJ. Cuttica, SK. de Oliveira, CB. Lindsley, CA. Pilkington, M. Punaro, A. Ravelli, AM. Reed, K. Rouster-Stevens, A. van Royen-Kerkhof, F. Dressler, C. Saad Magalhaes, T. Constantin, JE. Davidson, B. Magnusson, R. Russo, L. Villa, M. Rinaldi, H. Rockette, PA. Lachenbruch, FW. Miller, J. Vencovsky, N. Ruperto, . ,
520    9_
$a To develop response criteria for juvenile dermatomyositis (DM). We analysed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute per cent change in core set measures of minimal (≥30), moderate (≥45), and major (≥70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (p=0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (p<0.006). The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute per cent change in core set measures, with thresholds for minimal, moderate, and major improvement.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a konsensus $7 D032921
650    _2
$a dermatomyozitida $x terapie $7 D003882
650    _2
$a lidé $7 D006801
650    _2
$a hodnocení výsledků zdravotní péče $x normy $7 D017063
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a senzitivita a specificita $7 D012680
650    12
$a stupeň závažnosti nemoci $7 D012720
655    _2
$a konsensus - konference $7 D016446
655    _2
$a časopisecké články $7 D016428
655    _2
$a směrnice pro lékařskou praxi $7 D017065
655    _2
$a validační studie $7 D023361
700    1_
$a Aggarwal, Rohit $u University of Pittsburgh, Pittsburgh, Pennsylvania, USA. $7 gn_A_00002139
700    1_
$a Pistorio, Angela $u Istituto Giannina Gaslini, Servizio di Epidemiologia e Biostatistica, Genoa, Italy.
700    1_
$a Bayat, Nastaran $u NIEHS, NIH, Bethesda, Maryland, USA.
700    1_
$a Erman, Brian $u Social and Scientific Systems, Inc., Durham, North Carolina, USA.
700    1_
$a Feldman, Brian M $u The Hospital for Sick Children, Toronto, Ontario, Canada.
700    1_
$a Huber, Adam M $u IWK Health Centre, Halifax, Nova Scotia, Canada.
700    1_
$a Cimaz, Rolando $u University of Firenze, Florence, Italy.
700    1_
$a Cuttica, Rubén J $u Hospital de Niños Pedro de Elizalde, University of Buenos Aires, Buenos Aires, Argentina.
700    1_
$a de Oliveira, Sheila Knupp $u Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
700    1_
$a Lindsley, Carol B $u University of Kansas City Medical Center, Kansas City, Kansas, USA.
700    1_
$a Pilkington, Clarissa A $u Great Ormond Street Hospital for Children NHS Trust, London, UK.
700    1_
$a Punaro, Marilynn $u University of Texas Southwestern Medical Center, Dallas, Texas, USA.
700    1_
$a Ravelli, Angelo $u Istituto Giannina Gaslini, Pediatria II - Reumatologia, and Università degli Studi di Genova, Genoa, Italy.
700    1_
$a Reed, Ann M $u Duke University, Durham, North Carolina, USA.
700    1_
$a Rouster-Stevens, Kelly $u Emory University School of Medicine, Atlanta, Georgia, USA.
700    1_
$a van Royen-Kerkhof, Annet $u University Medical Centre Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands.
700    1_
$a Dressler, Frank $u Hannover Medical School, Hannover, Germany.
700    1_
$a Saad Magalhaes, Claudia $u Universidade Estadual Paulista Júlio de Mesquita Filho, Botucatu, Saõ Paulo, Brazil.
700    1_
$a Constantin, Tamás $u Semmelweis University, Budapest, Hungary.
700    1_
$a Davidson, Joyce E $u Royal Hospital for Sick Children, Glasgow, UK. Royal Hospital for Sick Children, Edinburgh, UK.
700    1_
$a Magnusson, Bo $u Karolinska University Hospital, Stockholm, Sweden.
700    1_
$a Russo, Ricardo $u Hospital de Pediatría Garrahan, Buenos Aires, Argentina.
700    1_
$a Villa, Luca $u Istituto Giannina Gaslini, Pediatria II - Reumatologia, PRINTO, Genoa, Italy.
700    1_
$a Rinaldi, Mariangela $u Istituto Giannina Gaslini, Pediatria II - Reumatologia, PRINTO, Genoa, Italy.
700    1_
$a Rockette, Howard $u University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
700    1_
$a Lachenbruch, Peter A $u NIEHS, NIH, Bethesda, Maryland, USA.
700    1_
$a Miller, Frederick W $u NIEHS, NIH, Bethesda, Maryland, USA.
700    1_
$a Vencovsky, Jiri $u Charles University, Prague, Czech Republic.
700    1_
$a Ruperto, Nicolino $u Istituto Giannina Gaslini, Pediatria II - Reumatologia, PRINTO, Genoa, Italy.
700    1_
$a ,
773    0_
$w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 76, č. 5 (2017), s. 782-791
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28385804 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170720124001 $b ABA008
999    __
$a ok $b bmc $g 1238833 $s 984065
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 76 $c 5 $d 782-791 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
LZP    __
$a Pubmed-20170720

Find record

Citation metrics

Archiving options